News
The 7 Peptides the FDA Decides On This July (PCAC Preview)
The FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to vote on whether seven peptides can be legally compounded under the 503A bulks list: BPC-157, TB-500, KPV, MOTS-c, DSIP (proposed name Emideltide), Semax and Epitalon. All seven were removed from Category 2 in April 2026, leaving them in regulatory limbo. The vote decides whether licensed compounding pharmacies can legally prepare them — or whether they stay gray-market only. Here is the honest part: none of these seven has strong human evidence. Six are Grade D (animal studies only) on our scale; Semax is Grade C (Russian trials, no Western replication). A favorable vote would legalize a supervised route — it would not make the science any stronger. This preview walks through each compound, its grade, and what a yes or no actually means for access.
Show sections
What is the July 2026 FDA peptide hearing?
The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which bulk substances licensed pharmacies may legally compound. Its July 23–24, 2026 meeting reviews seven peptides for the 503A bulks list — the list that separates a legal, supervised compounding route from a gray-market one.1
The backdrop: in April 2026 the FDA removed roughly a dozen peptides from "Category 2" and moved none into the approved "Category 1," leaving these compounds in limbo pending review.2 This hearing is the moment that limbo gets resolved for the first seven.
Which 7 peptides is the FDA reviewing?
All seven are on the docket across the two days. Here is each one with the grade our fixed rubric assigns and its current legal status — evidence and legality kept as separate questions, because a legal route would not change the science.
| Peptide | Evidence grade | Legal status | Read more |
|---|---|---|---|
| Semax | Grade C | Under FDA review | Semax → |
| BPC-157 | Grade D | Under FDA review | BPC-157 → |
| TB-500 | Grade D | Under FDA review | TB-500 → |
| KPV | Grade D | Under FDA review | KPV → |
| MOTS-c | Grade D | Under FDA review | MOTS-c → |
| Epitalon | Grade D | Under FDA review | Epitalon → |
| DSIP (Emideltide) | See tracker | Under FDA review | FDA tracker → |
The seventh, DSIP (proposed name Emideltide), does not yet have its own graded page here — its outcome is tracked on our FDA peptide status tracker alongside the other six.
What does the evidence actually say?
This is where the hype and the proof diverge. The most-searched names on the list — BPC-157 and TB-500, the "wolverine stack" — are Grade D: extensive rodent data, zero published human efficacy trials. KPV, MOTS-c and Epitalon are also Grade D. Semax is Grade C: a real drug in Russia with Russian clinical studies, but no Western RCT replication.
- Grade D (animal studies only): BPC-157, TB-500, KPV, MOTS-c, Epitalon
- Grade C (early / foreign human data only): Semax
- Not yet individually graded here: DSIP/Emideltide — small, dated human studies with mixed results
The number that should worry you more than the vote
FDA testing has found that a large share of online and compounded peptides were mislabeled, under-dosed, or contained ingredients not on the label. A legal compounding route reduces that risk; a gray-market vial does not. That gap — not the hype — is why we grade legal access at all.
What happens if PCAC votes yes — or no?
A yes for a given peptide clears the way for licensed 503A compounding pharmacies to prepare it — a legal, supervised route with a real prescriber and a regulated pharmacy behind it. A no leaves it research-only, meaning any product you find for sale is gray-market, regardless of how the label is worded.
A legal route is not an evidence upgrade
Even if every one of these seven is approved for compounding, the human evidence stays exactly where it is today. "Legal to compound" and "proven to work" are different questions. Watch for anyone who blurs them the day after the vote.
What this means if you're considering a peptide
Until the ruling, any clinic openly selling BPC-157 or TB-500 today is a compliance red flag. The honest move is to wait for the outcome, then use a licensed provider — never a "research use only" vial shop. If your actual goal is weight loss, no peptide on this docket beats an approved GLP-1 medication.
References
About this article
Written by Best Peptide For That Editorial, Best Peptide For That. Regulatory facts verified against FDA.gov and the Federal Register on the publication date. We are an independent publisher, not a medical provider — nothing here is medical or dosing advice. See our editorial policy for how we grade evidence.